Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-88 in Patients With Heart Failure With Chronic Mildly Reduced Ejection Fraction
NCT07509801Not yet recruiting
- Sponsor
- Guangzhou Manjing Biomedicine Technology Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
01
Overview
Randomised, single-blind trial of NT-88 in heart failure with mildly reduced ejection fraction (HFmrEF) (2 arms), sponsored by Guangzhou Manjing Biomedicine Technology Co., Ltd. Primary endpoint: Adverse Events. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
NT-88
03
Conditions
heart failure with mildly reduced ejection fraction (HFmrEF)
Beyond the preview
Go deeper on NCT07509801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07509801.